The anti-leukemia drug ponatinib attenuates NLRP3 inflammasome activation in macrophages
Abigail H. Evered, Daniel C. Shippy, Jaidynne N. Lash, Sophia F. Oliai, Tyler K. Ulland · 2026
Read The anti-leukemia drug ponatinib attenuates NLRP3 inflammasome activation in macrophages by Abigail H. Evered, Daniel C. Shippy, Jaidynne N. Lash, Sophia F. Oliai, Tyler K. Ulland (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13629504.txt.
Description
Abigail Evered and co-authors published this 2026 study on a leukemia drug that also calms a key inflammation switch. The switch, an assembly called the NLRP3 inflammasome, drives flare-ups in diabetes, gout, and Alzheimer's disease. In an earlier screen of 875 approved drugs, ponatinib stood out as a possible blocker that did not kill the test cells.
The team dosed mouse immune cells and found a level, one micromolar, that cut release of two inflammatory signals without harming the cells. The drug also reduced the processing of caspase-1, the cutter that arms those signals. Brain immune cells answered the same way at half that dose. The authors caution that the known heart risks of the drug mean dose and setting will decide any future use.
Catalog record
| CREATOR | Abigail H. Evered, Daniel C. Shippy, Jaidynne N. Lash, Sophia F. Oliai, Tyler K. Ulland |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |